Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024499 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
A Phase 2 study of Atopic Dermatitis and Atopic Dermatitis Eczema, sponsored by Shaperon.
- Active
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 12
- Study locations
NCT06024499 is a Phase 2 study of Atopic Dermatitis and Atopic Dermatitis Eczema that is active but no longer recruiting, run by Shaperon. The registered enrollment target is 210 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (65% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT06024499, a Phase 2 study of Atopic Dermatitis and Atopic Dermatitis Eczema, is active but no longer recruiting, sponsored by Shaperon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG HY209GEL Active
Study Locations (12)
Other
- Gachon University Gil Medical Center - Seoul
- Seoul National University Bundang Hospital - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
California
- RAOOF MD Dermatology - Encino
- L.A. Universal Research Center, Inc. - Los Angeles
- Zenith Research Inc. - Los Angeles
Alabama
- Cahaba Dermatology Skin Health Center - Birmingham
Maryland
- Continental Clinical Solutions, LLC - Towson
Michigan
- Revival Research Institute, LLC - Southfield
New York
- Sadick Dermatology - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06024499
The ClinicalTrials.gov registry entry for NCT06024499 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (65% lower). The listed sponsor is Shaperon, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06024499 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06024499 about?
NCT06024499 is a clinical study titled "Phase 2 Trial of HY209gel in Atopic Dermatitis Patients". This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
What is the current status of trial NCT06024499?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2024-03-01. Estimated completion is 2026-08-31.
What conditions does trial NCT06024499 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp.
What interventions are being tested in trial NCT06024499?
The interventions under investigation include: Placebo (OTHER), HY209GEL Active (DRUG).
Who is sponsoring clinical trial NCT06024499?
This trial is sponsored by Shaperon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06024499 being conducted?
This trial has 12 study locations across Alabama, California, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.